The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation
Abstract
Salmon sperm DNA, treated with the antitumor agent cis-diamminedichloroplatinum(II) (cis-DDP), was enzymatically degraded to (oligo)nucleotides. Four Pt-containing products were identified by 1H NMR after preparative chromatography on a diethylaminoethyl-Sephacel column at pH 8.8. In all identified adducts, comprising approximately 90% of the total Pt in the DNA, Pt was linked to the N7 atoms of the nucleobases guanine and adenine. The two major adducts were cis-Pt(NH3)2d(pGpG) and cis-Pt-(NH3)2d(pApG), both derived from intrastrand cross-links of cis-DDP on neighboring nucleobases. Only the d(pApG) but not the d(pGpA) adduct could be detected. Two minor adducts were Pt(NH3)3dGMP, resulting from monofunctionally bound cis-DDP to guanine, and cis-Pt(NH3)2d(GMP)2, originating from interstrand cross-links on two guanines as well as from intrastrand cross-links on two guanines separated by one or more bases. For analytical purposes we developed an improved method to determine cis-DDP adducts. Routinely, 40-micrograms samples of enzymatically degraded cis-DDP-treated DNA are now analyzed by separation of the mononucleotides and Pt-containing (oligo)nucleotides on the anion-exchange column Mono Q (FPLC) at pH 8.8 (completed within 14 min) and subsequent determination of the Pt content in the collected fractions by atomic absorption spectroscopy. The method was used to optimize the digestion conditions for cis-DDP-treated DNA. In kinetic studies on the formation of the various adducts, a clear preference of the Pt compound to react with guanines occurring in the base sequence d(pGpG) was established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ac, P., van Dijk, M., & Lohman, P. H. M. (1984) · PubMed · Cited by 170
Self-citationKerrison, S. J. S., & Sadler, P. J. (1977) · Journal of the Chemical Society Chemical Communications · doi:10.1039/c39770000861 · Cited by 110
Johnson, N. P., & Butour, J. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00414a060 · Cited by 9
Cited by
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Fuertes, M. A., Alonso, C., & Pérez, J. M. (2003) · Chemical Reviews · doi:10.1021/cr020010d · Cited by 893
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Marullo, R., Werner, E., Degtyareva, N., Moore, B., Altavilla, G., Ramalingam, S. S., & Doetsch, P. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081162 · Cited by 777
Why Does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands Available in the Cell?
Reedijk, J. (1999) · Chemical Reviews · doi:10.1021/cr980422f · Cited by 771
Self-citationTakahara, P. M., Rosenzweig, A. C., Frederick, C. A., & Lippard, S. J. (1995) · Nature · doi:10.1038/377649a0 · Cited by 769
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Synthetic Methods for the Preparation of Platinum Anticancer Complexes
Wilson, J. J., & Lippard, S. J. (2014) · Chemical Reviews · doi:10.1021/cr4004314 · Cited by 630
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA
Reedijk, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737293100 · Cited by 617
Self-citationThe DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
Goldstein, M., & Kastan, M. B. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-081313-121208 · Cited by 590
Improved understanding in platinium antitumour chemistry
Reedijk, J. (1996) · Chemical Communications · doi:10.1039/cc9960000801 · Cited by 589
Self-citationEastman, A. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90009-x · Cited by 539
Inhibition of transcription by platinum antitumor compounds
Todd, R. C., & Lippard, S. J. (2009) · Metallomics · doi:10.1039/b907567d · Cited by 539
Specific Binding of Chromosomal Protein HMG1 to DNA Damaged by the Anticancer Drug Cisplatin
Pil, P. M., & Lippard, S. J. (1992) · Science · doi:10.1126/science.1566071 · Cited by 496
Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA
Eastman, A. (1986) · Biochemistry · doi:10.1021/bi00361a026 · Cited by 458
Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA
Pinto, A. L., & Lippard, S. J. (1985) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(85)90001-0 · Cited by 437
Multiplicity of metal ion binding patterns to nucleobases
Lippert, B. (2000) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(00)00260-5 · Cited by 430
Lazarević, T., Rilak, A., & Bugarčić, Ž. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.007 · Cited by 428
Crystal Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA
Takahara, P. M., Frederick, C. A., & Lippard, S. J. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9625079 · Cited by 405
Metallomics as integrated biometal science
Haraguchi, H. (2004) · Journal of Analytical Atomic Spectrometry · doi:10.1039/b308213j · Cited by 399
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 384
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 370
Platinum Drug Distribution in Cancer Cells and Tumors
Klein, A. V., & Hambley, T. W. (2009) · Chemical Reviews · doi:10.1021/cr9001066 · Cited by 351
Recognition of cisplatin adducts by cellular proteins
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00142-7 · Cited by 349
The influence of structure on the activity and toxicity of Pt anti-cancer drugs
Hambley, T. W. (1997) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(97)00023-4 · Cited by 348
Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design
Reedijk, J. (2009) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200900054 · Cited by 343
Self-citationEnhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II)
Eastman, A., & Schulte, N. (1988) · Biochemistry · doi:10.1021/bi00413a022 · Cited by 312
DNA Polymerase γ in Mitochondrial DNA Replication and Repair
Graziewicz, M. A., Longley, M. J., & Copeland, W. C. (2006) · Chemical Reviews · doi:10.1021/cr040463d · Cited by 301
Baik, M.-H., Friesner, R. A., & Lippard, S. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036960d · Cited by 293
Bellon, S. F., Coleman, J. H., & Lippard, S. J. (1991) · Biochemistry · doi:10.1021/bi00246a021 · Cited by 291
Arnesano, F., & Natile, G. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.01.028 · Cited by 282
Preclinical Perspectives on Platinum Resistance
Kelland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00001 · Cited by 280
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
Chaney, S. G., & Sancar, A. (1996) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/88.19.1346 · Cited by 280
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells
Ferry, K. V., Hamilton, T. C., & Johnson, S. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00441-x · Cited by 275
Fichtinger-Schepman, A. M., van Oosterom, A. T., Lohman, P. H. M., & Berends, F. (2026) · PubMed · doi:10.82135/tno-230308 · Cited by 264
Self-citationLukin, M., & de los Santos, C. (2006) · Chemical Reviews · doi:10.1021/cr0404646 · Cited by 158
Reactive Oxygen Species a Double-Edged Sword for Mesothelioma
Benedetti, S., Nuvoli, B., Catalani, S., & Galati, R. (2015) · Oncotarget · doi:10.18632/oncotarget.4253 · Cited by 97
Metadata
- Authors
- Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1985-01-01
- Volume
- 24
- Issue
- 3
- Pages
- 707-713
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W1976453250
- Cited by
- 1,024
- References
- 3
- FWCI
- 13.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.